EX-10.17





 Exhibit 10.17 

 
 



 
 February 16, 2018 

Sarah Reiter 
 [Address] 

Dear Sarah: 
 On behalf of Arcadia Biosciences, Inc., henceforth
the “Company,” it is my pleasure to offer you the position of Chief Commercial Officer. This letter constitutes the entire agreement relating to the terms of your employment, except for the Confidentiality and Invention
Assignment Agreement between you and the Company, which must be executed as a condition of your employment, and the Severance and Change in Control Agreement between you and the Company, to be dated the Effective Date. 

Pursuant to the obligations spelled out in the Company’s Delegation of Authority Policy and Compensation Committee Charter, the terms of your
compensation and benefits must be approved by the Arcadia Board of Directors and Compensation Committee. Therefore, the terms set forth below shall be effective as of your date of hire, which is anticipated to be March 19, 2018 (the
“Effective Date”), conditioned upon such approval. It is anticipated that the Board and Compensation Committee shall review the terms of your compensation and benefits by March 1, 2018. If the terms as stated below are
not approved by the Board of Directors and Compensation Committee, you will be notified before the Effective Date. 
 Title and Base
Salary.  Your title will be Chief Commercial Officer and you will report directly to me. As of the Effective Date, your annual base salary shall be $265,000. 

Retention Bonus.  Should you be employed with the Company, and in good standing, you will be paid a retention bonus of $12,500 on the six-month anniversary of your Effective Date. In addition, you will be paid a retention bonus of $12,500 on the eighteen-month anniversary of your Effective Date. These bonuses are subject to standard tax
withholdings. 
 Bonus Compensation.  In addition to your base salary, you will be eligible for an annual incentive cash
bonus, as determined by the Company. Your annual incentive cash bonus shall have a target equal to 30% of your base salary as of the Effective Date, prorated for the portion of year during which you are employed by the Company. The target bonus and
its components, the Company performance goals, and your individual objectives shall be determined and documented each year by the Compensation Committee of the Board of Directors (the “Compensation Committee”). 

  
 202 Cousteau
Place      •      Suite 105      •      Davis, CA
95618      •      Tel: 530-756-7077      •      Fax:
530-756-7027      •      Web: www.arcadiabio.com 













 Equity Awards. 

Initial Grant 
 Concurrent with the commencement of your
employment with the Company, you will be granted an option to purchase shares of common stock of the Company (“Company Common Stock”) as follows, under the terms and conditions of a
Non-Qualified Stock Option Agreement (an “Option”): 
  

			
	 Strike Price*
	  	Number of Shares
	 FMV
	  	10,000

  

	* 	 FMV = the price of a share of RKDA common stock at close of market on the date of grant, which will be the
Effective Date; if FMV is greater than the listed strike price on the date of grant, such strike price shall be increased to reflect FMV. 



Your Option shall vest and become exercisable in accordance with the schedule below: 
  


	 	•	 	 25% of the shares subject to the Option will be fully vested and exercisable effective as of the first
anniversary of the Effective Date (the “Initial Vesting Date”), subject to your continued service through the Initial Vesting Date, and; 



 

	 	•	 	 75% of the shares subject to the Option will vest and become exercisable in 36 equal monthly installments
following the Initial Vesting Date, with the first such monthly vesting date taking place on April 19, 2019 and subsequent vesting dates on the last day of the next 35 months thereafter (with the last vesting date on March 19, 2022),
subject to your continued service through the applicable vesting date. 


 Other Grants 

The Company may grant equity awards to you from time to time, which will be subject to the terms of the applicable equity compensation plan or arrangement in
effect at the time of grant. The Compensation Committee will determine in its discretion whether you will be granted any such equity awards and the terms and conditions of any such awards in accordance with the terms of any applicable equity plan.
You should be aware that you may incur federal and state income taxes as a result of your receipt or the vesting of any equity compensation awards and it shall be your responsibility to pay any such applicable taxes. 

Severance and Change in Control Agreement.  You will have the benefits set forth in a Severance and Change in Control Agreement
between you and the Company to be executed on the Effective Date, a copy of which is attached hereto. 
 Other Benefits.  You
will be eligible for all Company adopted benefits, under the terms and conditions of such benefit plans. Your coverage for medical, dental, and vision benefits will become effective on the first of the month following your first thirty
(30) days of employment. 
 Your employment is “at-will,” which means that either you or the Company
may terminate the employment relationship at any time for any reason or for no reason (subject to the terms of the Severance Agreement). This at-will relationship may not be modified by any oral or implied
agreement. 

  
 202 Cousteau
Place      •      Suite 105      •      Davis, CA
95618      •      Tel: 530-756-7077      •      Fax:
530-756-7027      •      Web: www.arcadiabio.com 













 Conditions of Employment. 
  

	 	•	 	 In accordance with the Federal Immigration Reform and Control Act of 1986, we are required to have Employment
Eligibility Verification form I-9 on file. On your first day of employment, you will be asked to provide identification needed to complete the Form I-9 requirements.



  

	 	•	 	 You will sign the Company’s Confidentiality and Invention Agreement and the Company’s Severance and
Change in Control Agreement. 


  

	 	•	 	 You will be required to comply with the Company’s personnel policies outlined in the Employee Handbook or as
adopted from time to time by the Company. 


  

	 	•	 	 You represent to the Company that you are not subject to any obligation, contractual or otherwise, that prevents
or restricts you from becoming employed by the Company, or that creates any potential or actual conflict of interest, or places the Company at risk of liability for hiring you. 



 

	 	•	 	 You represent and agree that you have not taken, and will not import or use any proprietary or trade secret
information belonging to any other person or entity, including your former employer, in the discharge of your duties for the Company. 



The information contained in this letter represents the entire substance of Arcadia’s offer of employment to you and is contingent upon successful
completion of all pre-and post-employment checks. If all the above terms and conditions meet with your approval, please sign this letter and return it by March 1, 2018. If this document is not returned by
this date, this offer of employment shall be withdrawn. 
 I very much look forward to you joining the Arcadia team. If you should have any questions,
please feel free to call me. 
 Sincerely, 
  

	
	/s/RAJENDRA KETKAR
	 Rajendra (Raj) Ketkar
 President &
Chief Executive Officer


 ACCEPTED BY: 
  

	
	/s/SARAH REITER
	Sarah Reiter

  

	
	February 16, 2018
	Date


  
 202 Cousteau
Place      •      Suite 105      •      Davis, CA
95618      •      Tel: 530-756-7077      •      Fax:
530-756-7027      •      Web: www.arcadiabio.com 













 



 
 SEVERANCE AND CHANGE IN CONTROL AGREEMENT 

This Severance and Change in Control Agreement (the “Agreement”) is made and entered into by and between Sarah Reiter
(“Executive”) and Arcadia Biosciences, Inc. (the “Company”), effective as of the latest date set forth by the signatures of the parties hereto below (the “Effective Date”). 

RECITALS 

1.    The Compensation Committee of the Board of Directors of the Company (the “Committee”)
recognizes that it is possible that the Company could terminate Executive’s at-will employment with the Company and from time to time the Company may consider the possibility of an acquisition by another
company or other change in control transaction. The Committee also recognizes that such considerations can be a distraction to Executive and can cause Executive to consider alternative employment opportunities. The Committee has determined that it
is in the best interests of the Company and its stockholders to assure that the Company will have the continued dedication and objectivity of Executive, notwithstanding the possibility, threat or occurrence of such a termination of employment or the
occurrence of a Change in Control (as defined herein) of the Company. 
 2.    The Committee believes that it is in the
best interests of the Company and its stockholders to provide Executive with an incentive to continue her employment with the Company and to motivate Executive to maximize the value of the Company for the benefit of its stockholders. 

3.    The Committee believes that it is imperative to provide Executive with certain severance benefits upon
Executive’s termination of employment and with certain additional benefits following a Change in Control. These benefits will provide Executive with enhanced financial security and incentive and encouragement to remain with the Company
notwithstanding the possibility of a Change in Control. 
 4.    The Company and Executive have entered into an offer
letter dated February 16, 2018 (the “Offer Letter”). 
 5.    The Company and Executive
wish to restate the terms of Executive’s severance and benefits (whether or not in connection with a Change in Control) and replace any and all such provisions providing for severance and/or change in control payments, as set forth below. All
other terms and conditions of the Offer Letter will remain in full force and effect. 

  
 202 Cousteau
Place      •      Suite 105      •      Davis, CA
95618      •      Tel: 530-756-7077      •      Fax:
530-756-7027      •      Web: www.arcadiabio.com 













 6.    Certain capitalized terms used in the Agreement are defined in
Section 6 below. 
 AGREEMENT 

NOW, THEREFORE, in consideration of the mutual covenants contained herein, the parties hereto agree as follows: 

1.    Term of Agreement.  The Agreement shall terminate on the third (3rd) anniversary of the Effective Date (the “Term End Date”); provided, however, that if as of the Term End Date Executive is receiving benefits under Section 3 of this
Agreement, then the Agreement shall continue in effect until such date as all of the obligations of the parties hereto with respect to this Agreement have been satisfied. 

2.    At-Will Employment.  The Company and Executive acknowledge
that, notwithstanding this Agreement and any benefits provided for herein, Executive’s employment is and will continue to be at-will, as defined under applicable law. If Executive’s employment
terminates for any reason, including (without limitation) any termination of employment not set forth in Section 3, Executive will not be entitled to any payments, benefits, damages, awards or compensation other than the payment of accrued but
unpaid wages and vacation, if any, as required by law, and any unreimbursed reimbursable expenses or pursuant to written agreements with the Company, including equity award agreements. 

3.    Severance Benefits. 

(a)    Termination without Cause and not in Connection with a Change in Control.  If the Company
terminates Executive’s employment with the Company for a reason other than Cause, Executive becoming Disabled, or Executive’s death, at any time other than during the twelve (12)-month period immediately following the Effective Date (the
“Initial Year of Service”) or the twelve (12)-month period immediately following a Change in Control, then, subject to Section 4, Executive will receive the following severance benefits from the Company: 

(i)    Accrued Compensation.  The Company will pay Executive all accrued but unpaid vacation, expense
reimbursements, wages, and other benefits due to Executive under any Company-provided plans, policies, and arrangements. 

(ii)    Severance Payment.  Executive will receive continuing payments of severance for a period of six
(6) months (such number of months, the “Standard Severance Period”) from the date of such termination of employment at a rate equal to Executive’s base salary as in effect immediately prior to the date
of Executive’s termination of employment (disregarding any reduction in base salary that triggers the right to termination for Good Reason), less all required tax withholdings and other applicable deductions, which will be paid in accordance
with the Company’s regular payroll procedures. 
 (iii)    Continued Employee Benefits.  If
Executive elects continuation coverage pursuant to the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (“COBRA”) for Executive and Executive’s eligible dependents, within the time period prescribed
pursuant to COBRA, the Company will reimburse 

  
 202 Cousteau
Place      •      Suite 105      •      Davis, CA
95618      •      Tel: 530-756-7077      •      Fax:
530-756-7027      •      Web: www.arcadiabio.com 













 
Executive for the COBRA premiums for such coverage (at the coverage levels in effect immediately prior to Executive’s termination or resignation) until the earlier of (A) the end of the
Standard Severance Period, or (B) the date upon which Executive and/or Executive’s eligible dependents becomes covered under similar plans. COBRA reimbursements will be made by the Company to Executive consistent with the Company’s
normal expense reimbursement policy and will be taxable to the extent required to avoid adverse consequences to Executive or the Company under either Code Section 105(h) or the Patient Protection and Affordable Care Act of 2010. 

(iv)    Payments or Benefits Required by Law.  Executive will receive such other compensation or
benefits from the Company as may be required by law. 
 (b)    Termination without Cause or Resignation for Good
Reason in Initial Year of Service or in Connection with a Change in Control.  If during the Initial Year of Service or during the twelve (12)-month period immediately following a Change in Control, (x) the Company terminates
Executive’s employment with the Company for a reason other than Cause, Executive becoming Disabled, or Executive’s death, or (y) Executive resigns from such employment for Good Reason, then, subject to Section 4, Executive will
receive the following severance benefits from the Company in lieu of the benefits described in Section 3(a) above: 

(i)    Accrued Compensation.  The Company will pay Executive all accrued but unpaid vacation, expense
reimbursements, wages, and other benefits due to Executive under any Company-provided plans, policies, and arrangements. 

(ii)    Severance Payment.  Executive will receive continuing payments of severance for a period of
twelve (12) months (such number of months, the “Enhanced Severance Period”) from the date of such termination of employment at a rate equal to Executive’s base salary as in effect immediately prior to
the date of Executive’s termination of employment (disregarding any reduction in base salary that triggers the right to termination for Good Reason), less all required tax withholdings and other applicable deductions, which will be paid in
accordance with the Company’s regular payroll procedures. 
 (iii)    Continued Employee
Benefits.  If Executive elects continuation coverage pursuant to the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (“COBRA”) for Executive and Executive’s eligible dependents, within
the time period prescribed pursuant to COBRA, the Company will reimburse Executive for the COBRA premiums for such coverage (at the coverage levels in effect immediately prior to Executive’s termination or resignation) until the earlier of
(A) the end of the Enhanced Severance Period, or (B) the date upon which Executive and/or Executive’s eligible dependents becomes covered under similar plans. COBRA reimbursements will be made by the Company to Executive consistent
with the Company’s normal expense reimbursement policy and will be taxable to the extent required to avoid adverse consequences to Executive or the Company under either Code Section 105(h) or the Patient Protection and Affordable Care Act
of 2010. 
 (iv)    Equity.  Executive will be entitled to accelerated vesting as to one hundred
percent (100%) of the then-unvested portion of all of Executive’s outstanding equity awards. 

  
 202 Cousteau
Place      •      Suite 105      •      Davis, CA
95618      •      Tel: 530-756-7077      •      Fax:
530-756-7027      •      Web: www.arcadiabio.com 













 (v)    Payments or Benefits Required by
Law.  Executive will receive such other compensation or benefits from the Company as may be required by law. 

(c)    Disability; Death.  If Executive’s employment with the Company is terminated due to Executive
becoming Disabled or Executive’s death, then Executive or Executive’s estate (as the case may be) will (i) receive the earned but unpaid base salary through the date of termination of employment, (ii) receive all accrued
vacation, expense reimbursements and any other benefits due to Executive through the date of termination of employment in accordance with Company-provided or paid plans, policies and arrangements, and (iii) not be entitled to any other
compensation or benefits from the Company except to the extent required by law (for example, COBRA). 

(d)    Voluntary Resignation; Termination for Cause.  If Executive voluntarily terminates
Executive’s employment with the Company (other than for Good Reason following a Change in Control) or if the Company terminates Executive’s employment with the Company for Cause, then Executive will (i) receive her or her earned but
unpaid base salary through the date of termination of employment, (ii) receive all accrued vacation, expense reimbursements and any other benefits due to Executive through the date of termination of employment in accordance with established
Company-provided or paid plans, policies and arrangements, and (iii) not be entitled to any other compensation or benefits (including, without limitation, accelerated vesting of any equity awards) from the Company except to the extent provided
under agreement(s) relating to any equity awards or as may be required by law (for example, COBRA). 
 (e)    Timing
of Payments.  Subject to Section 4, payment of the severance and benefits hereunder shall be made or commence to be made as soon as practicable following Executive’s termination of employment. 

(f)    Exclusive Remedy.  In the event of a termination of Executive’s employment with the Company
pursuant to Section 3(a) or Section 3(b), the provisions of this Section 3 are intended to be and are exclusive and in lieu of any other rights or remedies to which Executive or the Company may otherwise be entitled, whether at law,
tort or contract, in equity, or under this Agreement (other than the payment of accrued but unpaid wages, as required by law, and any unreimbursed reimbursable expenses). Executive will be entitled to no other severance, benefits, compensation or
other payments or rights upon a termination of employment, including, without limitation, any severance payments and/or benefits provided in the Employment Agreement, other than those benefits expressly set forth in Section 3 of this Agreement
or pursuant to written equity award agreements with the Company. 
 4.    Conditions to Receipt of Severance.

 (a)    Release of Claims Agreement.  In the event of a termination of Executive’s employment
with the Company pursuant to Section 3(a) or Section 3(b), the receipt of any severance payments or benefits pursuant to this Agreement is subject to Executive signing and not revoking a separation agreement and release of claims in a form
acceptable to the Company (the “Release”), which must become effective no later than the sixtieth (60th) day following Executive’s termination of employment (the
“Release Deadline”), and if not, Executive will forfeit any right to severance payments or benefits under this Agreement. To become effective, the Release must be executed by Executive


  
 202 Cousteau
Place      •      Suite 105      •      Davis, CA
95618      •      Tel: 530-756-7077      •      Fax:
530-756-7027      •      Web: www.arcadiabio.com 













 
and any revocation periods (as required by statute, regulation, or otherwise) must have expired without Executive having revoked the Release. In addition, in no event will severance payments or
benefits be paid or provided until the Release actually becomes effective. If the termination of employment occurs at a time during the calendar year where the Release Deadline could occur in the calendar year following the calendar year in which
Executive’s termination of employment occurs, then any severance payments or benefits under this Agreement that would be considered Deferred Payments (as defined in Section 4(d)(i)) will be paid on the first payroll date to occur during
the calendar year following the calendar year in which such termination occurs, or such later time as required by (i) the payment schedule applicable to each payment or benefit as set forth in Section 3, (ii) the date the Release becomes
effective, or (iii) Section 4(d)(ii); provided that the first payment shall include all amounts that would have been paid to Executive if payment had commenced on the date of Executive’s termination of employment. 

(b)    Non-solicitation.  Executive agrees, to the extent
permitted by applicable law, that in the event the Executive receives severance pay or other benefits pursuant to Section 3(a) or 3(b) above, for the number of months of severance provided to Executive pursuant to Section 3(a)(ii) or
3(b)(ii), as applicable, immediately following the date of Executive’s termination, Executive, as a condition to receipt of severance pay and benefits under Sections 3(a) and 3(b), will not directly or indirectly, solicit, induce, recruit, or
encourage any employee of the Company to leave her or her employment either for Executive or for any other entity or person. In the event Executive violates the provisions of this Section 4(b), all severance pay and other benefits to which
Executive may otherwise be entitled pursuant to Section 3(a) or 3(b) shall cease immediately. 
 The covenant contained in this
Section 4(b) hereof shall be construed as a series of separate covenants, one for each country, province, state, city or other political subdivision in which the Company currently engages in its business or, during the term of this Agreement,
becomes engaged in its business. Except for geographic coverage, each such separate covenant shall be deemed identical in terms to the covenant contained in this Section 4(b). If, in any judicial proceeding, a court refuses to enforce any of
such separate covenants (or any part thereof), then such unenforceable covenant (or such part) shall be eliminated from this Agreement to the extent necessary to permit the remaining separate covenants (or portions thereof) to be enforced. In the
event that the provisions of this Section 4(b) are deemed to exceed the time, geographic or scope limitations permitted by applicable law, then such provisions shall be reformed to the maximum time, geographic or scope limitations, as the case
may be, permitted by applicable law. 
 (c)    Confidential Information Agreement and Other
Requirements.  Executive’s receipt of any payments or benefits under Section 3 (except for those required by law) will be subject to Executive continuing to comply with the terms of the Confidential Information Agreement (as
defined in Section 9) executed by Executive in favor of the Company and the provisions of this Agreement. 

(d)    Section 409A. 

(i)    Notwithstanding anything to the contrary in this Agreement, no severance pay or benefits to be paid or provided to
Executive, if any, pursuant to this Agreement that, when considered together with any other severance payments or separation benefits, are considered deferred compensation not exempt under Section 409A (together, the “Deferred
Payments”) will be paid or otherwise provided until Executive 

  
 202 Cousteau
Place      •      Suite 105      •      Davis, CA
95618      •      Tel: 530-756-7077      •      Fax:
530-756-7027      •      Web: www.arcadiabio.com 













 
has a “separation from service” within the meaning of Section 409A. And for purposes of this Agreement, any reference to “termination of employment,”
“termination” or any similar term shall be construed to mean a “separation from service” within the meaning of Section 409A. Similarly, no severance payable to Executive, if any, pursuant to this Agreement that otherwise
would be exempt from Section 409A pursuant to Treasury Regulation Section 1.409A-1(b)(9) will be payable until Executive has a “separation from service” within the meaning of
Section 409A. 
 (ii)    Notwithstanding anything to the contrary in this Agreement, if Executive is a
“specified employee” within the meaning of Section 409A at the time of Executive’s termination of employment (other than due to death), then the Deferred Payments, if any, that are payable within the first six (6) months
following Executive’s separation from service, will become payable on the first payroll date that occurs on or after the date six (6) months and one (1) day following the date of Executive’s separation from service. All
subsequent Deferred Payments, if any, will be payable in accordance with the payment schedule applicable to each payment or benefit. Notwithstanding anything herein to the contrary, if Executive dies following Executive’s separation from
service, but prior to the six (6) month anniversary of the separation from service, then any payments delayed in accordance with this paragraph will be payable in a lump sum as soon as administratively practicable after the date of
Executive’s death and all other Deferred Payments will be payable in accordance with the payment schedule applicable to each payment or benefit. Each payment, installment and benefit payable under this Agreement is intended to constitute a
separate payment for purposes of Section 1.409A-2(b)(2) of the Treasury Regulations. 

(iii)    Without limitation, any amount paid under this Agreement that satisfies the requirements of the “short-term
deferral” rule set forth in Section 1.409A-1(b)(4) of the Treasury Regulations is not intended to constitute Deferred Payments for purposes of clause (i) above. 

(iv)    Without limitation, any amount paid under this Agreement that qualifies as a payment made as a result of an
involuntary separation from service pursuant to Section 1.409A-1(b)(9)(iii) of the Treasury Regulations that does not exceed the Section 409A Limit is not intended to constitute Deferred Payments for
purposes of clause (i) above. Any payment intended to qualify under this exemption must be made within the allowable time period specified in Section 1.409A-1(b)(9)(iii) of the Treasury Regulations.

 (v)    To the extent that reimbursements or in-kind benefits under this
Agreement constitute non-exempt “nonqualified deferred compensation” for purposes of Section 409A, (1) all reimbursements hereunder shall be made on or prior to the last day of the calendar
year following the calendar year in which the expense was incurred by Executive, (2) any right to reimbursement or in-kind benefits shall not be subject to liquidation or exchange for another benefit, and
(3) the amount of expenses eligible for reimbursement or in-kind benefits provided in any calendar year shall not in any way affect the expenses eligible for reimbursement or in-kind benefits to be provided, in any other calendar year. 

  
 202 Cousteau
Place      •      Suite 105      •      Davis, CA
95618      •      Tel: 530-756-7077      •      Fax:
530-756-7027      •      Web: www.arcadiabio.com 













 (vi)    Any tax gross-up that
Executive is entitled to receive under this Agreement or otherwise shall be paid to Executive no later than December 31st of the calendar year following the calendar year in which Executive remits
the related taxes. 
 (vii)    Notwithstanding any other provision of this Agreement to the contrary, in no event shall
any payment under this Agreement that constitutes “nonqualified deferred compensation” for purposes of Code Section 409A be subject to offset by any other amount unless otherwise permitted by Code Section 409A. 

(viii)    The foregoing provisions are intended to be exempt from or comply with the requirements of Section 409A so
that none of the severance payments and benefits to be provided hereunder will be subject to the additional tax imposed under Section 409A, and any ambiguities or ambiguous terms herein will be interpreted to be exempt or so comply. The Company
and Executive agree to work together in good faith to consider amendments to this Agreement and to take such reasonable actions which are necessary, appropriate or desirable to avoid imposition of any additional tax or income recognition prior to
actual payment to Executive under Section 409A. 
 5.    Limitation on Payments. 

(a)    Anything in this Agreement to the contrary notwithstanding, if any payment or benefit Executive would receive from
the Company or otherwise (“Payment”) would (i) constitute a “parachute payment” within the meaning of Section 280G of the Code; and (ii) but for this sentence, be subject to the excise tax imposed by
Section 4999 of the Code (the “Excise Tax”), then such Payment shall be equal to the Reduced Amount. The “Reduced Amount” shall be either (x) the largest portion of the Payment that
would result in no portion of the Payment being subject to the Excise Tax; or (y) the largest portion, up to and including the total, of the Payment, whichever amount, after taking into account all applicable federal, state and local employment
taxes, income taxes, and the Excise Tax (all computed at the highest applicable marginal rate), results in Executive’s receipt, on an after-tax basis, of the greater amount of the Payment. Any reduction
made pursuant to this Section 5(a) shall be made in accordance with the following order of priority: (i) stock options whose exercise price exceeds the fair market value of the optioned stock (“Underwater Options”),
(ii) Full Credit Payments (as defined below), that are payable in cash, (iii) non-cash Full Credit Payments that are taxable, (iv) non-cash Full Credit
Payments that are not taxable, (v) Partial Credit Payments (as defined below) and (vi) non-cash employee welfare benefits. In each case, reductions shall be made in reverse chronological order such
that the payment or benefit owed on the latest date following the occurrence of the event triggering the excise tax will be the first payment or benefit to be reduced (with reductions made pro-rata in the
event payments or benefits are owed at the same time). “Full Credit Payment” means a payment, distribution or benefit, whether paid or payable or distributed or distributable pursuant to the terms of this Agreement or
otherwise, that if reduced in value by one dollar reduces the amount of the parachute payment (as defined in Section 280G of the Code) by one dollar, determined as if such payment, distribution or benefit had been paid or distributed on the
date of the event triggering the excise tax. “Partial Credit Payment” means any payment, distribution or benefit that is not a Full Credit Payment. In no event shall the Executive have any discretion with respect to the
ordering of payment reductions. 

  
 202 Cousteau
Place      •      Suite 105      •      Davis, CA
95618      •      Tel: 530-756-7077      •      Fax:
530-756-7027      •      Web: www.arcadiabio.com 













 (b)    Unless the Company and Executive otherwise agree in writing, any
determination required under this Section 5 will be made in writing by an independent firm (the “Firm”), whose determination will be conclusive and binding upon Executive and the Company for all purposes. For purposes of
making the calculations required by this Section 5, the Firm may make reasonable assumptions and approximations concerning applicable taxes and may rely on reasonable, good faith interpretations concerning the application of Sections 280G and
4999 of the Code. The Company and Executive will furnish to the Firm such information and documents as the Firm may reasonably request in order to make a determination under this Section 5. The Company will bear all costs the Firm may
reasonably incur in connection with any calculations contemplated by this Section 5. 
 6.    Definition of
Terms.  The following terms referred to in this Agreement will have the following meanings: 

(a)    Cause. “Cause” means: 

(i)    Executive’s conviction of, or pleading guilty or nolo contendere to, any felony or a lesser crime involving
dishonesty or moral turpitude; 
 (ii)    Executive’s willful failure to perform Executive’s duties and
responsibilities to the Company or Executive’s violation of any written Company policy or agreement; 

(iii)    Executive’s commission of any act of fraud, embezzlement, dishonesty against the Company or any other
intentional misconduct that has caused or is reasonably expected to result in injury to the Company; 

(iv)    Executive’s unauthorized use or disclosure of any proprietary information or trade secrets of the Company or
any other party to whom the Executive owes an obligation of nondisclosure as a result of her or her relationship with the Company; 

(v)    Executive’s failure to reasonably cooperate with the Company in any investigation or formal proceeding after
receiving a written request to do so; or 
 (vi)    Executive’s material breach of any of her obligations under
any written agreement or covenant with the Company. 
 (vii)    Executive’s continuing failure to communicate and
fully disclose material information to the Company, the failure of which would adversely impact the Company or may result in a violation of state or federal law. 

(b)    Change in Control.  “Change in Control” means the occurrence of any of the
following: 
 (i)    The consummation of a merger or consolidation of the Company with or into another entity or any
other corporate reorganization, if the Company’s stockholders immediately prior to such merger, consolidation or reorganization cease to directly or indirectly own immediately after such merger, consolidation or reorganization at least a
majority of the combined voting power of the continuing or surviving entity’s securities outstanding immediately after such merger, consolidation or other reorganization; 

  
 202 Cousteau
Place      •      Suite 105      •      Davis, CA
95618      •      Tel: 530-756-7077      •      Fax:
530-756-7027      •      Web: www.arcadiabio.com 













 (ii)    The consummation of the sale, transfer or other disposition of
all or substantially all of the Company’s assets (other than (x) to a corporation or other entity of which at least a majority of its combined voting power is owned directly or indirectly by the Company, (y) to a corporation or other
entity owned directly or indirectly by the stockholders of the Company in substantially the same proportions as their ownership of the common stock of the Company or (z) to a continuing or surviving entity described in Section 6(b)(i) in
connection with a merger, consolidation or corporate reorganization which does not result in a Change in Control under Section 6(b)(i)); 

(iii)    A change in the effective control of the Company which occurs on the date that a majority of members of the
Company’s Board of the Directors (the “Board”) is replaced during any twelve (12) month period by Directors whose appointment or election is not endorsed by a majority of the members of the Board prior to the date
of the appointment or election. For purposes of this clause, if any Person (as defined below in Section 6(b)(iv)) is considered to be in effective control of the Company, the acquisition of additional control of the Company by the same Person
will not be considered a Change in Control; or 
 (iv)    The consummation of any transaction as a result of which any
Person becomes the “beneficial owner” (as defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), directly or indirectly, of
securities of the Company representing at least fifty percent (50%) of the total voting power represented by the Company’s then outstanding voting securities. For purposes of this clause (iv), the term “person” shall have the same
meaning as when used in sections 13(d) and 14(d) of the Exchange Act but shall exclude: 
 (1)    a trustee or other
fiduciary holding securities under an employee benefit plan of the Company or an affiliate of the Company; 
 (2)    a
corporation or other entity owned directly or indirectly by the stockholders of the Company in substantially the same proportions as their ownership of the common stock of the Company; 

(3)    the Company; and 

(4)    a corporation or other entity of which at least a majority of its combined voting power is owned directly or
indirectly by the Company. 
 A transaction shall not constitute a Change in Control if its sole purpose is to change the state of the
Company’s incorporation or to create a holding company that will be owned in substantially the same proportions by the persons who held the Company’s securities immediately before such transactions. For the avoidance of doubt, an initial
public offering of the common stock of the Company shall not constitute a Change in Control for purposes of this Agreement. 

(c)    Code.  “Code” means the Internal Revenue Code of 1986, as amended. 

  
 202 Cousteau
Place      •      Suite 105      •      Davis, CA
95618      •      Tel: 530-756-7077      •      Fax:
530-756-7027      •      Web: www.arcadiabio.com 














(d)    Disability.  “Disability” means that because of a physical or medical
impairment, Executive is unable, with or without a reasonable accommodation, to perform the essential functions pertaining to Executive’s position with the Company for a period exceeding 4 months. 

(e)    Good Reason.  “Good Reason” means Executive’s termination of
employment within ninety (90) days following the expiration of any cure period (discussed below) following the occurrence, without Executive’s consent, of one or more of the following: 

(i)    A material reduction of Executive’s duties, authority or responsibilities, relative to Executive’s
duties, authority or responsibilities in effect immediately prior to such reduction; provided, however, that a reduction in duties, authority or responsibilities solely by virtue of the Company being acquired and made part of a larger entity (as,
for example, when the Chief Executive Officer of the Company remains as such following a Change of Control but is not made the Chief Executive Officer of the acquiring corporation) will not constitute Good Reason; 

(ii)    A material reduction in Executive’s base compensation (except where there is a reduction applicable to all
similarly situated executive officers generally); provided, that a reduction of less than ten percent (10%) will not be considered a material reduction in base compensation; 

(iii)    A material change in the geographic location of Executive’s primary work facility or location; provided,
that a relocation of less than thirty-five (35) miles from Executive’s then-present work location will not be considered a material change in geographic location; or 

(iv)    A material breach by the Company of a material provision of this Agreement or a failure of a successor entity in
the Change of Control to assume this Agreement; 
 Executive will not resign for Good Reason without first providing the Company with
written notice within sixty (60) days of the event that Executive believes constitutes “Good Reason” specifically identifying the acts or omissions constituting the grounds for Good Reason and a reasonable cure period of not less than
thirty (30) days following the date of such notice during which such condition must not have been cured. 

(f)    Section 409A.  “Section 409A” means Code
Section 409A, and the final regulations and any guidance promulgated thereunder or any state law equivalent. 

(g)    Section 409A Limit.  “Section 409A Limit”
will mean two (2) times the lesser of: (i) Executive’s annualized compensation based upon the annual rate of pay paid to Executive during the Executive’s taxable year preceding the Executive’s taxable year of her or her
separation from service as determined under Treasury Regulation Section 1.409A-1(b)(9)(iii)(A)(1) and any Internal Revenue Service guidance issued with respect thereto; or (ii) the maximum amount
that may be taken into account under a qualified plan pursuant to Section 401(a)(17) of the Internal Revenue Code for the year in which Executive’s separation from service occurred. 

  
 202 Cousteau
Place      •      Suite 105      •      Davis, CA
95618      •      Tel: 530-756-7077      •      Fax:
530-756-7027      •      Web: www.arcadiabio.com 













 7.    Successors. 

(a)    The Company’s Successors.  Any successor to the Company (whether direct or
indirect and whether by purchase, merger, consolidation, liquidation or otherwise) to all or substantially all of the Company’s business and/or assets will assume the obligations under this Agreement and agree expressly to perform the
obligations under this Agreement in the same manner and to the same extent as the Company would be required to perform such obligations in the absence of a succession. For all purposes under this Agreement, the term “Company” will include
any successor to the Company’s business and/or assets which executes and delivers the assumption agreement described in this Section 7(a) or which becomes bound by the terms of this Agreement by operation of law. 

(b)    Executive’s Successors.  The terms of this Agreement and all rights of Executive hereunder
will inure to the benefit of, and be enforceable by, Executive’s personal or legal representatives, executors, administrators, successors, heirs, distributees, devisees and legatees. 

8.    Arbitration. 

(a)    Arbitration.  In consideration of Executive’s employment with the Company, its promise to
arbitrate all employment-related disputes, and Executive’s receipt of the compensation, pay raises and other benefits paid to Executive by the Company, at present and in the future, Executive agrees that any and all controversies,
claims, or disputes with anyone (including the Company and any employee, officer, director, stockholder or benefit plan of the Company in their capacity as such or otherwise) arising out of, relating to, or resulting from Executive’s employment
with the Company or termination thereof, including any breach of this Agreement, will be subject to binding arbitration under the Arbitration Rules set forth in California Code of Civil Procedure Section 1280 through 1294.2, including
Section 1281.8 (the “Act”), and pursuant to California law. The Federal Arbitration Act shall also apply with full force and effect, notwithstanding the application of procedural rules set forth under the Act. 

(b)    Dispute Resolution.  Disputes that Executive agrees to arbitrate, and thereby agrees to waive
any right to a trial by jury, include any statutory claims under local, state, or federal law (except those which are expressly excluded by statute, state law, or applicable court decision from being resolved by mandatory arbitration),
including, but not limited to, claims under Title VII of the Civil Rights Act of 1964, the Americans with Disabilities Act of 1990, the Age Discrimination in Employment Act of 1967, the Older Workers Benefit Protection Act, the Sarbanes Oxley Act,
the Worker Adjustment and Retraining Notification Act, the California Fair Employment and Housing Act, the Family and Medical Leave Act, the California Family Rights Act, the California Labor Code, claims of harassment, discrimination, and wrongful
termination, and any statutory or common law claims. Executive further understands that this Agreement to arbitrate also applies to any disputes that the Company may have with Executive. 

(c)    Procedure.  Executive agrees that any arbitration will be administered by the Judicial
Arbitration & Mediation Services, Inc. (“JAMS”), pursuant to its Employment Arbitration Rules & Procedures (the “JAMS Rules”). The arbitrator shall have the power to decide any
motions brought by any party to the arbitration, including motions for summary judgment and/or adjudication, motions to dismiss and demurrers, and motions for class certification, prior to any arbitration hearing. The


  
 202 Cousteau
Place      •      Suite 105      •      Davis, CA
95618      •      Tel: 530-756-7077      •      Fax:
530-756-7027      •      Web: www.arcadiabio.com 













 
arbitrator shall have the power to award any remedies available under applicable law, and the arbitrator shall award attorneys’ fees and costs to the prevailing party, except as prohibited
by law. The Company will pay for any administrative or hearing fees charged by the administrator or JAMS, and all arbitrator’s fees, except that Executive shall pay any filing fees associated with any arbitration that Executive initiates, but
only so much of the filing fee as Executive would have instead paid had Executive filed a complaint in a court of law. Executive agrees that the arbitrator shall administer and conduct any arbitration in accordance with California law, including the
California Code of Civil Procedure and the California Evidence Code, and that the arbitrator shall apply substantive and procedural California law to any dispute or claim, without reference to the rules of conflict of law. To the extent that the
JAMS Rules conflict with California law, California law shall take precedence. The decision of the arbitrator shall be in writing. Any arbitration under this Agreement shall be conducted in Alameda County, California. 

(d)    Remedy.  Except as provided by the Act, arbitration shall be the sole, exclusive, and final remedy
for any dispute between Executive and the Company. Accordingly, except as provided by the Act and this Agreement, neither Executive nor the Company will be permitted to pursue court action regarding claims that are subject to arbitration.
Notwithstanding, the arbitrator will not have the authority to disregard or refuse to enforce any lawful Company policy, and the arbitrator will not order or require the Company to adopt a policy not otherwise required by law that the Company has
not adopted. 
 (e)    Administrative Relief.  Executive is not prohibited from pursuing an
administrative claim with a local, state, or federal administrative body or government agency that is authorized to enforce or administer laws related to employment, including, but not limited to, the Department of Fair Employment and Housing, the
Equal Employment Opportunity Commission, the National Labor Relations Board, or the Workers’ Compensation Board. However, Executive may not pursue court action regarding any such claim, except as permitted by law. 

(f)    Voluntary Nature of Agreement.  Executive acknowledges and agrees that Executive is executing this
Agreement voluntarily and without any duress or undue influence by the Company or anyone else. Executive further acknowledges and agrees that Executive has carefully read this Agreement and that Executive has asked any questions needed for Executive
to understand the terms, consequences and binding effect of this Agreement and fully understands it. Finally, Executive agrees that Executive has been provided an opportunity to seek the advice of an attorney of Executive’s choice before
signing this Agreement. 
 9.    Confidential Information.  Executive agrees to continue to comply with
and be bound by the Confidentiality and Intellectual Property Rights Agreement (the “Confidential Information Agreement”) entered into by and between Executive and the Company, dated February 16, 2018. 

  
 202 Cousteau
Place      •      Suite 105      •      Davis, CA
95618      •      Tel: 530-756-7077      •      Fax:
530-756-7027      •      Web: www.arcadiabio.com 













 10.    Notice. 

(a)    General.  Notices and all other communications contemplated by this Agreement will be in writing
and will be deemed to have been duly given when personally delivered or when mailed by U.S. registered or certified mail, return receipt requested and postage prepaid. In the case of Executive, mailed notices will be addressed to him or her at the
home address which he or she most recently communicated to the Company in writing. In the case of the Company, mailed notices will be addressed to its corporate headquarters, and all notices will be directed to the attention of its General Counsel.

 (b)    Notice of Termination.  Any termination by the Company for Cause or by Executive for Good
Reason will be communicated by a notice of termination to the other party hereto given in accordance with Section 10(a) of this Agreement. Such notice will indicate the specific termination provision in this Agreement relied upon, will set
forth in reasonable detail the facts and circumstances claimed to provide a basis for termination under the provision so indicated, and will specify the termination date (which will be not more than thirty (30) days after the giving of such
notice). The failure by Executive to include in the notice any fact or circumstance which contributes to a showing of Good Reason will not waive any right of Executive hereunder or preclude Executive from asserting such fact or circumstance in
enforcing her rights hereunder. 
 11.    Miscellaneous Provisions. 

(a)    No Duty to Mitigate.  Executive will not be required to mitigate the amount of any payment
contemplated by this Agreement, nor will any such payment be reduced by any earnings that Executive may receive from any other source. 

(b)    Waiver.  No provision of this Agreement will be modified, waived or discharged unless the
modification, waiver or discharge is agreed to in writing and signed by Executive and by an authorized officer of the Company (other than Executive). No waiver by either party of any breach of, or of compliance with, any condition or provision of
this Agreement by the other party will be considered a waiver of any other condition or provision or of the same condition or provision at another time. 

(c)    Headings.  All captions and section headings used in this Agreement are for convenient reference
only and do not form a part of this Agreement. 
 (d)    Entire Agreement.  This Agreement constitutes
the entire agreement of the parties hereto and supersedes in their entirety all prior or contemporaneous representations, understandings, undertakings or agreements (whether oral or written and whether expressed or implied) of the parties with
respect to the subject matter hereof, including, without limitation, any severance provisions contained in the Employment Agreement. Executive acknowledges and agrees that this Agreement encompasses all the rights of Executive to any severance
payments and/or benefits based on the termination of Executive’s employment and Executive hereby agrees that he or she has no such rights except as stated herein. No waiver, alteration, or modification of any of the provisions of this Agreement
will be binding unless in writing and signed by duly authorized representatives of the parties hereto and which specifically mention this Agreement. 

(e)    Choice of Law.  The validity, interpretation, construction and performance of this Agreement will
be governed by the laws of the State of California (with the exception of its conflict of laws provisions). 

  
 202 Cousteau
Place      •      Suite 105      •      Davis, CA
95618      •      Tel: 530-756-7077      •      Fax:
530-756-7027      •      Web: www.arcadiabio.com 













 (f)    Severability.  The invalidity or
unenforceability of any provision or provisions of this Agreement will not affect the validity or enforceability of any other provision hereof, which will remain in full force and effect. 

(g)    Withholding.  All payments made pursuant to this Agreement will be subject to withholding of
applicable income, employment and other taxes, as determined in the Company’s reasonable judgment. 

(h)    Counterparts.  This Agreement may be executed in counterparts, each of which will be deemed an
original, but all of which together will constitute one and the same instrument. 
 [Signature Page Follows] 

  
 202 Cousteau
Place      •      Suite 105      •      Davis, CA
95618      •      Tel: 530-756-7077      •      Fax:
530-756-7027      •      Web: www.arcadiabio.com 













 IN WITNESS WHEREOF, each of the parties has executed this Agreement, in the case of
the Company by its duly authorized officer, as of the day and year set forth below. 
  

							
	COMPANY	 		 	ARCADIA BIOSCIENCES, INC.
		 		 	By:	 	/s/RAJENDRA KETKAR
		 		 	Title:	 	President & CEO
		 		 	Date:	 	February 16, 2018

  

							
	EXECUTIVE	 		 	SARAH REITER
		 		 	By:	 	/s/SARAH REITER
		 		 	Date: 	 	February 16, 2018


  
 202 Cousteau
Place      •      Suite 105      •      Davis, CA
95618      •      Tel: 530-756-7077      •      Fax:
530-756-7027      •      Web: www.arcadiabio.com